Clinical Evaluation of New Chinese Herbal Medicines for Syndromes： A Preliminary Study on Target Design

ZHANG Li; ZHONG Mengyuan; XING Yongfa; LI Duojing; WU Zheying; HUANG Yuhong

doi:10.13288/j.11-2166/r.2024.16.018

您当前的位置：

首页 >

文章列表页 >

Clinical Evaluation of New Chinese Herbal Medicines for Syndromes： A Preliminary Study on Target Design

更新时间：2024-08-12

- Clinical Evaluation of New Chinese Herbal Medicines for Syndromes： A Preliminary Study on Target Design
- Journal of Traditional Chinese Medicine Vol. 65, Issue 16, Pages: 1730-1733(2024)
- 作者机构：
  
  1.天津中医药大学第二附属医院，天津市河北区增产道69号，300250
  2.天津中医药大学
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2024.16.018
  CLC：
- Received：17 August 2023，
  
  Revised：2024-06-23，
  
  Published：17 August 2024
- 稿件说明：
移动端阅览
张莉,钟梦媛,邢永发等.证候类中药新药临床评价的靶式设计初探[J].中医杂志,2024,65(16):1730-1733.

ZHANG Li,ZHONG Mengyuan,XING Yongfa,et al.Clinical Evaluation of New Chinese Herbal Medicines for Syndromes： A Preliminary Study on Target Design[J].Journal of Traditional Chinese Medicine,2024,65(16):1730-1733.
张莉,钟梦媛,邢永发等.证候类中药新药临床评价的靶式设计初探[J].中医杂志,2024,65(16):1730-1733. DOI： 10.13288/j.11-2166/r.2024.16.018.

ZHANG Li,ZHONG Mengyuan,XING Yongfa,et al.Clinical Evaluation of New Chinese Herbal Medicines for Syndromes： A Preliminary Study on Target Design[J].Journal of Traditional Chinese Medicine,2024,65(16):1730-1733. DOI： 10.13288/j.11-2166/r.2024.16.018.

摘要

当前证候类中药新药临床评价方法及评价模式存在一定局限性，尚缺乏符合中医药特点的临床评价体系。基于中医药“辨证论治”“方证对应”的特色，在病证结合基础上提出靶式设计模型、假说及其应用范围。在充分考虑病、证双重因素基础上，通过同一证型人群中不同证素的差异来区分“靶心”“中环”“外环”以判定证候符合程度的差异，进而将同一证候人群按照“靶心”“中环”“外环”分层分析，实现证候类中药新药的精准定位，尝试为中医药辨证论治、精准干预提供研究思路及方法。

Abstract

There are certain limitations in the current clinical evaluation methods and evaluation modes of new Chinese herbal medicines for syndromes， and there is a lack of a clinical evaluation system that meets the characteristics of traditional Chinese medicine （TCM）. Based on the characteristics of TCM "syndrome differentiation and treatment" and "correspondence of formulas and syndromes"， the target design model， hypothesis and its scope of application are proposed on the basis of the combination of diseases and syndromes. On the basis of fully considering the dual factors of diseases and syndromes， we distinguished the "centre of the target"， "middle ring" and "outer ring" through the differences of different signs and symptoms in people with same syndrome， in order to determine the degree of conformity of the syndrome. Then， the population with same syndrome could be analysed according to the "centre of the target"， "middle ring" and "outer ring"， so as to achieve the precise positioning of new Chinese herbal medicines for syndromes， and try to provide research ideas and methods for syndrome differentiation and treatment of TCM and precise intervention.

关键词

Keywords

references

中华中医药学会 . 中医药重大科学问题和工程技术难题［J］. 中医杂志， 2019 ， 60 （ 12 ）： 991 - 1000 .

郭蕾，韩俊莉，刘宁 . 论现代医学架构下中医证候临床疗效评价体系的瓶颈［J］. 中华中医药杂志， 2017 ， 32 （ 8 ）： 3357 - 3360 .

国家药品监督管理局 . 国家药监局关于发布证候类中药新药临床研究技术指导原则的通告（2018年第109号）［EB/OL］.（ 2018-11-06 ）［ 2024-06-23 ］. http：//www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/201811061557-01473.html http://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/201811061557-01473.html .

郭思瑞，徐文峰，金鹏飞 . 基本药物综合评价方法研究进展［J］. 中国医院用药评价与分析， 2023 ， 23 （ 4 ）： 510 - 512 .

袁冰 . 建立适合中医学的科学的临床评价体系［J］. 医学与哲学， 2020 ， 41 （ 10 ）： 56 - 63 .

班娜，曹世奎 . 中国创新药物研发现状［J］. 应用化学， 2022 ， 39 （ 5 ）： 857 - 858 .

唐镜波 . 临床药物评价的意义与方法［J］. 中国药房， 1996 ， 7 （ 6 ）： 243 - 246 .

陈可冀 . 病证结合治疗观与临床实践［J］. 中国中西医结合杂志， 2011 ， 31 （ 8 ）： 1016 - 1017 .

姜雯，姜泉，周新尧，等 . 基于“病证经纬”理论探讨中医风湿病药靶方略［J］. 现代中西医结合杂志， 2022 ， 31 （ 12 ）： 1701 - 1704 .

黄煌 . 方证相应与“方-病-人”思维模式［J］. 江苏中医药， 2023 ， 55 （ 5 ）： 1 - 5 .

胡大一 . 以疾病为中心，还是以患者为中心［J］. 中华高血压杂志， 2023 ， 31 （ 1 ）： 1 .

陈银潇，李兆栋，李佳颖，等 . 中西医结合背景下“辨证论治”传承创新的路径探讨［J］. 天津中医药大学学报， 2023 ， 42 （ 2 ）： 158 - 161 .

马莲，王可彬，吴圣贤 . 基于“理论创新”视角探讨证候类中药新药的研发［J］. 中国中药杂志， 2020 ， 45 （ 20 ）： 5048 - 5056 .

张曦，石作荣 . 整体观视角下探讨肿瘤的辨病与辨证论治［J］．辽宁中医杂志， 2024 ， 51 （ 1 ）： 74 - 76 .

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Development of a Core Outcome Set for Clinical Evaluation of Chronic Pulmonary Heart Disease Treated with Traditional Chinese Medicine Therapy

Evolutionary Law of Syndrome and Syndrome Elements during the Malignant Transformation of Chronic Hepatitis B

Preliminary Discussion on the Influencing Factors of Traditional Chinese Medicine Syndrome under the Multidisciplinary Diagnosis and Treatment Model of Malignant Tumors

Traditional Chinese Medicine Efficacy Evaluation Items for Lower Extremity Arteriosclerosis Obliterans Based on Bayesian Network and Association Rule

Construction of Core Outcome Set for Diabetic Foot in Traditional Chinese Medicine Clinical Researches

Related Author

NIU Baihan

ZHANG Mingyan

JI Zhaochen

PANG Bo

HU Haiyin

ZHANG Junhua

YU Simiao

DING Xia

Related Institution

The First Affiliated Hospital of Henan University of Chinese Medicine

National Institute of TCM Constitution and Preventive Medicine，Beijing University of Chinese Medicine

School of Traditional Chinese Medicine，Beijing University of Chinese Medicine

The Fifth Medical Center of Chinese PLA General Hospital

Dongzhimen Hospital，Beijing University of Chinese Medicine

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰